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ABSTRACT
Background Hospitalisation due to acute
exacerbations of COPD (AECOPD) is common, and
subsequent mortality high. The DECAF score was derived
for accurate prediction of mortality and risk stratification
to inform patient care. We aimed to validate the DECAF
score, internally and externally, and to compare its
performance to other predictive tools.
Methods The study took place in the two hospitals
within the derivation study (internal validation) and in
four additional hospitals (external validation) between
January 2012 and May 2014. Consecutive admissions
were identified by screening admissions and searching
coding records. Admission clinical data, including DECAF
indices, and mortality were recorded. The prognostic
value of DECAF and other scores were assessed by the
area under the receiver operator characteristic (AUROC)
curve.
Results In the internal and external validation cohorts,
880 and 845 patients were recruited. Mean age was
73.1 (SD 10.3) years, 54.3% were female, and mean
(SD) FEV1 45.5 (18.3) per cent predicted. Overall
mortality was 7.7%. The DECAF AUROC curve for
inhospital mortality was 0.83 (95% CI 0.78 to 0.87) in
the internal cohort and 0.82 (95% CI 0.77 to 0.87) in
the external cohort, and was superior to other
prognostic scores for inhospital or 30-day mortality.
Conclusions DECAF is a robust predictor of mortality,
using indices routinely available on admission. Its
generalisability is supported by consistent strong
performance; it can identify low-risk patients (DECAF
0–1) potentially suitable for Hospital at Home or early
supported discharge services, and high-risk patients
(DECAF 3–6) for escalation planning or appropriate early
palliation.
Trial registration number UKCRN ID 14214.
INTRODUCTION
Acute exacerbations of COPD (AECOPD) account
for one in eight hospital admissions,1 and are asso-
ciated with worsening symptoms, lung function,
health-related quality of life, and mortality risk.2–6
Inhospital mortality is reported to be between
4.4% and 7.7%.7–10 Clinicians are unable accur-
ately to predict prognosis in patients hospitalised
with AECOPD.11 A robust prediction tool, which
stratifies patients according to mortality risk, may
help inform management, including Hospital at
Home (HAH) or early supported discharge (ESD)
for low-risk groups, and early escalation or appro-
priate palliation for high-risk groups.
The Dyspnoea, Eosinopenia, Consolidation,
Acidaemia, and atrial Fibrillation (DECAF) score
was derived in a large cohort of consecutive
patients hospitalised with AECOPD, is simple to
apply at the bedside and predicts inhospital mortal-
ity using indices routinely available on admission.12
The score comprises five predictors, the strongest
of which is stable state dyspnoea, as measured by
the extended Medical Research Council Dyspnoea
score (eMRCD; table 1).13
In the derivation study (the original study, in
which the DECAF score was developed), DECAF
showed strong performance and was superior to
other tools designed or proposed for patients with
AECOPD,12 namely APACHE II,14 BAP-65,15
CAPS16 and CURB-65.17
The 2014 UK National COPD audit recom-
mended that the DECAF score be documented on
all patients admitted with an AECOPD but noted
that validation was required,7 which is essential
to prove the generalisability of a prognostic
score.18 We present temporal and geographical
validation of the DECAF score and re-examine its
predictive performance for short and medium
term mortality in a large multicentre cohort of
patients hospitalised with AECOPD. Two cohorts
are presented: the internal validation cohort
assesses performance of DECAF in both hospitals
from the original derivation study, but over a dif-
ferent time period; the external validation study
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Key messages
What is the key question?
▸ Does the DECAF score predict inhospital
mortality in patients admitted to hospital with
an acute exacerbation of COPD?
What is the bottom line?
▸ In both internal and external validation cohorts,
DECAF is a robust predictor of inhospital
mortality using indices that are routinely
available at the time of admission, and can be
easily applied at the bedside.
Why read on?
▸ Accurate risk stratification may be used to
inform clinical decision-making, although
further research is required to quantify the
impact on clinical and financial outcomes.
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assesses the performance and generalisability of DECAF in
four hospitals from different geographical areas. Since the
DECAF score could identify low-risk patients (DECAF 0–1)
who might benefit from HAH or ESD schemes, we report a
detailed analysis of this subgroup.
METHODS
Study design and participation
Six UK hospitals participated between January 2012 and May
2014. Sites A and B formed the internal validation cohort
and sites C–F formed the external validation cohort (table 2).
The latter were selected to ensure wide variation in structures
of care and population characteristics (COPD prevalence,
socioeconomic factors and rurality). In participating hospitals,
consecutive patients admitted with AECOPD were identified.
In the internal validation cohort hospitals, the DECAF indices
are recorded as part of routine practice. This allowed the
period of the study to be extended retrospectively to enhance
recruitment; patients were primarily identified from a broad
coding records search (discharge codes). However this was
cross-referenced with existing records of patients identified by
respiratory specialist nursing and physiotherapy teams. In the
external validation cohort to identify consecutive admissions
of patients with AECOPD, all medical admissions were
screened prospectively. This involved dedicated staff attending
the medical admissions unit and base wards. Coding records
were also reviewed to maximise patient capture.
Inclusion criteria were: a primary diagnosis of pneumonic or
non-pneumonic exacerbation of COPD; preadmission spirometric
evidence of airflow obstruction; age ≥35 years and smoking
history of ≥10 cigarette pack-years. Exclusion criteria were: previ-
ous inclusion in the present study and any illness, other than
COPD, likely to limit survival to less than 1 year (principally
metastatic malignancy). Spirometry showing airflow obstruction
performed at any time point prior to admission was accepted,
and both primary and secondary care records were searched.
Treatment was at the discretion of attending clinicians, and not
influenced by the research team. Antibiotic therapy was informed
by the prescribing policy of individual sites. Ethical approval was
granted by the local research ethics committee.
Data collection
Clinical indices on admission, and demographic and survival
data were collected.12 In our derivation study,12 118 patients
had oxygen saturation (SpO2) >92% while breathing room air,
of whom none had an arterial pH of <7.30 (DECAF acidaemia
score=1). In the present study, therefore, if the attending phys-
ician deemed that arterial blood gas (ABG) sampling was
unnecessary and SpO2 was >92% without supplementary
oxygen, it was presumed that the arterial pH was ≥7.30.19
Outcome
The primary outcome was inhospital mortality prediction, with
comparison of DECAF risk groups between the derivation and
validation cohorts. Secondary outcomes included assessment of
Table 1 eMRCD score, guidance note for eMRCD and DECAF score
eMRCD score
‘In the past 3 months, when you were feeling at your best, which of the following statements best describes your level of
breathlessness?’ (Circle)
Only breathless on strenuous exertion 1
Breathless hurrying on the level or walking up a slight hill 2
Walks slower than contemporaries, or stops after walking on the level for 15 min 3
Stops for breath after walking 100 m, or for a few minutes, on the level 4
Too breathless to leave the house unassisted but independent in washing and/or dressing 5a
Too breathless to leave the house unassisted and requires help with washing and dressing 5b
Guidance notes:
Remember that you are asking the patient about their level of breathlessness on a good day over the preceding 3 months, not breathlessness during an exacerbation/on
admission.
A patient only achieves a higher grade if they are as breathless as defined in that higher grade.
▸ eg, if worse than defined in eMRCD 3, but not as bad as eMRCD 4, they remain eMRCD 3.
A key distinction is between eMRCD 4 and eMRCD 5a/5b:
▸ only score 5a or 5b if the patient cannot leave the house without assistance.
▸ if a patient can only walk 30 to 40 metres, but can leave the house unassisted, they are eMRCD 4.
▸ if a patient can walk 5 or 10 metres, perhaps from their front door to a car, but need a wheelchair otherwise, they require assistance: eMRCD 5a or 5b. Simple walking
aids do not constitute assistance.
If a patient requires assistance in personal washing and dressing they are eMRCD 5b. If they only require assistance in washing or dressing they are eMRCD 5a. Remember to
ask about putting on socks and shoes.
If patients are limited for a reason other than breathlessness, score based on their functional limitation.
DECAF Score Circle
D eMRCD 5a (Too breathless to leave the house unassisted but independent in washing and/or dressing)
eMRCD 5b (Too breathless to leave the house unassisted and requires help with washing and dressing)
1
2
E Eosinopenia (eosinophils <0.05×109/L) 1
C Consolidation 1
A Moderate or severe acidaemia (pH <7.3) 1
F atrial Fibrillation (including history of paroxysmal atrial Fibrillation) 1
Total
eMRCD, extended Medical Research Council dyspnoea score.
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Table 2 Baseline characteristics of patients by site
Internal validation n=880 External validation n=845
Site A
n=459
Site B
n=421
Site C
n=307
Site D
n=271
Site E
n=171
Site F
n=96
All sites
N=1725 p Value
Recruitment period Jan 12-May 13 Jan 12-May 13 Aug 13- May 14 Jul 13-Apr 14 Apr 13-Feb 14 Feb 14-Apr 14 Jan 12-May 14 N/A
Recruitment/day 0.89 0.82 1.07 0.89 0.58 1.12 0.86 N/A
Died inhospital, % 9.8 7.8 7.5 6.6 4.7 5.2 7.7 0.27
DECAF 0–1, % 44.4 46.6 47.6 34.3 44.4 61.5 44.9 0.00018
DECAF 2, % 30.9 26.6 29.6 28.0 32.7 21.9 28.9 0.33
DECAF 3–6, % 24.6 26.8 22.8 37.6 22.8 16.7 26.3 0.00013
Sociodemographics
Age, years* 73.5 (9.9) 73.9 (10.3) 73.5 (10.4) 72.0 (9.8) 72.4 (10.7) 70.7 (11.4) 73.1 (10.3) 0.025
Female, % 56.4 58.0 56.4 40.6 58.5 53.1 54.3 0.00012
Smoking pack-years, n† 41 (30–58) 40 (30–55) 44 (30–60) 40 (30–56) 45 (30–60) 40 (30–59) 40 (30–59) 0.71
Current smoking, % 38.2 40.9 39.7 36.2 36.1 47.4 39.1 0.41
Institutional care, % 8.9 5.0 2.9 2.6 4.1 5.2 5.2 0.0018
Markers of disease severity
eMRCD score 1–4, % 44.7 49.2 49.5 35.1 44.4 68.8 46.4 <0.0001
eMRCD score 5a, % 39.7 36.6 30.3 24.7 42.1 24.0 34.3 <0.0001
eMRCD score 5b, % 15.7 14.3 20.2 40.2 13.5 7.3 19.3 <0.0001
Hospital admissions in previous year, n† 0 (0–1) 0 (0–1) 1 (0–1) 1 (0–2) 1 (0–2) 1.5 (0–3) 0 (0–1) <0.0001
FEV1% predicted* 47.8 (19.4) 48.5 (18.5) 44.8 (18.2) 40.6 (14.9) 40.5 (15.4) 46.6 (20.4) 45.5 (18.3) <0.0001
LTOT, % 15.7 16.2 13.4 17.7 26.8 17.7 16.9 0.014
Cor pulmonale, % 5.9 7.4 10.4 8.5 8.9 2.1 7.5 0.052
LT prednisolone, % 8.1 6.7 5.5 10.0 9.0 7.3 7.6 0.38
Comorbidity
IHD, % 27.5 32.3 31.9 27.7 26.6 27.1 29.4 0.46
CVD, % 13.3 12.4 13.1 13.7 5.9 11.5 12.3 0.14
Diabetes, % 11.3 11.9 15.0 13.0 14.8 17.7 13.1 0.40
Atrial fibrillation, % 14.8 20.7 16.9 17.7 16.4 14.6 17.2 0.33
LVD, % 8.1 9.3 18.2 10.0 4.7 3.2 9.9 <0.0001
Cognitive impairment, % 5.0 5.0 6.8 8.5 3.6 1.0 5.5 0.049
Anxiety, % 13.9 13.3 37.6 20.3 7.1 9.4 18.1 <0.0001
Depression, % 23.3 18.3 33.6 25.5 19.4 9.4 23.1 <0.0001
Admission clinical data
Acute confusion, % 12.9 12.9 8.7 8.9 6.6 6.3 10.6 0.060
Respiratory rate, n* 26.5 (6.8) 25.7 (6.0) 21.8 (4.5) 24.1 (6.2) 23.9 (6.2) 23.5 (6.3) 24.7 (6.3) <0.0001
Pulse rate, n* 104.9 (21.0) 102.8 (22.8) 97.1 (18.3) 102.2 (20.5) 104.7 (21.6) 99.7 (18.4) 102.3 (21.0) <0.0001
sBP, mm Hg* 136.5 (30.3) 145.2 (26.6) 130.8 (22.0) 135.0 (26.5) 134.5 (22.9) 133.6 (24.2) 137.1 (26.9) <0.0001
dBP, mm Hg* 74.6 (17.0) 80.0 (19.0) 71.6 (15.8) 77.2 (18.5) 77.3 (19.6) 73.2 (13.7) 76.0 (17.9) <0.0001
Temperature, °C† 36.9 (36.3–37.6) 36.5 (36.0–37.2) 36.8 (36.4–37.3) 36.5 (36.0–37.1) 36.5 (35.9–37.0) 36.7 (36.0–37.0) 36.7 (36.2–37.3) <0.0001
Oxygen saturation† 92 (87–94) 93 (88–95) 94 (91–95) 93 (90–95) 93 (90–95) 92 (91–95) 93 (89–95) <0.0001
Pedal oedema, % 25.8 21.6 26.8 27.0 32.7 5.3 24.9 <0.0001
BMI, kg/m2* 25.1 (6.8) 24.9 (6.8) 24.5 (6.4) 25.4 (6.4) 24.1 (6.5) N/A 24.9 (6.6) 0.28
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the optimal thresholds for pH and eosinopenia, prediction of
30-day mortality by DECAF and comparison with other prognos-
tic scores (APACHE II,14 BAP-65,15 CAPS16 and CURB-6517).
Length of stay (LOS) was compared across DECAF scores.
Statistical methods
Based on an expected sensitivity of 70%, an SE of the estimate
of sensitivity of 5% required a minimum of 840 patients in both
the internal and external validation cohorts.20 For indices with
<20% missing values, data were imputed using the Markov
Chain Monte Carlo method on IBM SPSS Statistics 22, with
linear and logistic regression for continuous and categorical vari-
ables.21 A large number of variables (n=67) were used as pre-
dictors for variables with missing data to create five datasets.
Baseline population characteristics and outcome were
described using proportions, means with SDs or medians with
IQRs, and compared using Fisher’s exact test, analysis of vari-
ance or Welch, and Kruskal–Wallis test. Clinical scores’ perform-
ance was assessed by the area under the receiver operator
characteristic (AUROC) curve and compared with each other by
the method of DeLong with and without multiple imputation;22
results were pooled using Rubin’s method.21 Logistic regression
was used to model DECAF indices to provide ORs, 95% CIs
and coefficients to assess the weighting of indices. Calibration
was assessed with the Hosmer–Lemeshow statistic.23 The
optimal thresholds for pH and eosinophil count were reassessed
by visual inspection of the ROC curve. Subgroup analyses
assessed outcome in patients at low risk according to DECAF,
with (a) coexisting consolidation or (b) acidaemia.
RESULTS
Patient characteristics
Data were obtained for 880 and 845 patients in the internal and
external validation cohorts, respectively. Across both cohorts,
mean (SD) age was 73.1 (10.3) years, 54.3% were female and
most had severe airflow limitation; mean (SD) FEV1 45.5 (18.3)
per cent predicted. The median DECAF score was 2 (IQR 1–3),
28.3% had radiographic consolidation and 18.9% had an acid-
aemic exacerbation (pH<7.35). In keeping with the UK
national audit,7 rates of comorbidity were high, notably ischae-
mic heart disease and diabetes (table 2).
Significant differences between sites included: the proportion
requiring institutional care, radiographic consolidation, age,
gender, DECAF score, severity of airflow limitation, the number
of previous hospital admissions and the proportion with signifi-
cant weight loss. Sites were broadly similar for comorbidity,
though the proportions with left ventricular dysfunction, anxiety
or depression differed. All of these factors were also significantly
different between internal and external validation cohorts, except
for DECAF score and left ventricular dysfunction.
Missing data
There were no missing mortality or DECAF data. The percent-
age of complete data for each risk score was: BAP-65 97.2%,
CURB-65 96.5%, CAPS 85.9% and APACHE II 73.2%. For
individual variables, missing data were PaO2 12.6%, albumin
12.2%, pH 12.1%, GCS 11.7%, potassium 3.3%, confusion
2.6%, temperature 2.6%, mean arterial blood pressure 1.8%,
respiratory rate 1.8%, systolic BP 1.7%, diastolic BP 1.7%,
heart rate 1.4%, haematocrit 1.2%, creatinine 0.5%, white
blood cell count 0.2%, urea 0.1% and sodium 0.1%.
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Validation of the DECAF score
The AUROCDECAF curve for inhospital mortality was: internal
validation=0.83 (95% CI 0.78 to 0.87), external valid-
ation=0.82 (95% CI 0.77 to 0.87) and overall=0.82 (95% CI
0.79 to 0.85). The discrimination of the DECAF score was sig-
nificantly stronger than CURB-65, CAPS, APACHE II and
BAP-65 for 30-day mortality. For inhospital mortality, the
DECAF score was again superior, except in comparison with
APACHE II where the higher discriminatory strength of DECAF
was not significant (table 3 and figure 1).
In a complete case analysis (without imputation), the conclu-
sions were unchanged for 30-day mortality; for inhospital mor-
tality, AUROCDECAF curve was again the highest, but was not
statistically superior to CAPS (p=0.068) or BAP-65 (p=0.060).
Table 4 shows mortality rates, sensitivity and specificity by
DECAF score in the overall validation cohort, and mortality by
DECAF risk group compared with our derivation cohort.12
Compared with the derivation study, mortality overall and in
the high-risk group was lower. Higher DECAF scores were again
associated with higher mortality, though absolute numbers were
small for DECAF 5 and 6 groups. The model was a satisfactory fit
to the data (Hosmer–Lemeshow statistic=0.48, Nagelkerke
R2=24%). The previously assigned weightings of the DECAF
score were confirmed on logistic regression (see online supplemen-
tary table S1), and eMRCD score remained the strongest predictor.
Compared with the traditional MRCD scale,24 eMRCD had
superior prognostic strength for inhospital mortality:
AUROCeMRCD=0.74 (95% CI 0.70 to 0.78) versus
AUROCtraditional MRCD=0.68 (95% CI 0.64 to 0.72);
p<0.0001. In the subpopulation with a pneumonic exacerbation
(n=485), eMRCD was again superior to the MRCD scale:
AUROCeMRCD=0.67 (95% CI 0.60 to 0.73) versus
AUROCMRCD=0.62 (95% CI 0.56 to 0.69); p=0.0070.
CURB-65 predicts 30-day mortality in patients with com-
munity acquired pneumonia, and is commonly applied to
patients with a pneumonic exacerbation of COPD
(pAECOPD). In the validation cohort, for the subgroup of
patients with pAECOPD (n=489), the DECAF score was a
non-significantly stronger predictor of 30-day mortality than
CURB-65: AUROCDECAF=0.76 (95% CI 0.70 to 0.81) versus
AUROCCURB-65=0.68 (95% CI 0.62 to 0.74); p=0.057
(figure 2; online supplementary table S2 shows sensitivity and
specificity for DECAF scores).
When patients with pAECOPD were pooled across the deriv-
ation and validation cohort (n=788), DECAF was superior for
30-day (AUROCDECAF=0.75 (95% CI 0.71 to 0.79) vs
AUROCCURB-65=0.66 (95% CI 0.62 to 0.71); p<0.0001) and
inpatient mortality (AUROCDECAF=0.76 (95% CI 0.71 to 0.80)
vs AUROCCURB-65=0.70 (95% CI 0.65 to 0.75); p=0.024).
The superior performance of DECAF is of particular import-
ance for patients deemed at low risk by each score, who may be
considered suitable for home treatment. Patients with a low-risk
DECAF score had a lower inhospital mortality compared with
those with a low-risk CURB-65 score: DECAF=1.6% (2/122)
versus CURB-65=7.2% (17/237); p=0.026. There were similar
differences for 30-day mortality: DECAF 0–1=3.3% (4/122)
versus CURB-65 0–1=10.1% (24/237); p=0.022 (see online
supplementary table S3).
Table 3 Comparison of AUROC curves for DECAF and other scores (with imputation)
Prognostic score
AUROC curve (95% CI)
Inhospital death Comparison with DECAF, p value
AUROC curve (95% CI)
30-day death Comparison with DECAF, p value
DECAF 0.82 (0.79 to 0.85) N/A 0.79 (0.75 to 0.83) N/A
CURB-65 0.76 (0.72 to 0.80) 0.0057 0.73 (0.69 to 0.77) 0.0051
CAPS 0.77 (0.73 to 0.81) 0.038 0.73 (0.69 to 0.77) 0.0083
APACHE II 0.78 (0.74 to 0.82) 0.083 0.72 (0.68 to 0.77) 0.0039
BAP-65 0.77 (0.73 to 0.81) 0.038 0.72 (0.68 to 0.76) 0.0021
AUROC curves of each prognostic score compared with DECAF by method of DeLong.22
AUROC, area under the receiver operator characteristic.
Figure 1 Receiver operator characteristic curves of prognostic scores for inhospital (A) and 30-day mortality (B).
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The optimal thresholds for eosinophil count and pH were
reassessed. On visual inspection of the ROC curve, the optimal
cut-off for eosinopenia was unchanged (0.05×109/L).12 For pH
threshold, both 7.30 and 7.35 offered similar discrimination.
The 7.30 threshold identified in the derivation study was
retained for consistency, and because no deaths occurred among
58 patients with a low-risk DECAF score and non-scoring acid-
aemia (7.30-7.34). Only three patients had a DECAF score of 1
due to a pH<7.30, all of whom survived.
Patients with SpO2 >92% without supplemental oxygen in
whom ABG sampling was deemed unnecessary were assigned a
score of 0 for the pH component of DECAF. Of the 209 such
patients overall, only 6 died (2.9%); this total included 0/52
with a DECAF score of 0 and 2/67 with a DECAF score of 1.
Time to death in those who died during the index admission
and LOS in those who survived to discharge, by DECAF score,
are shown in table 5. Among survivors, higher DECAF scores
were associated with longer LOS.
DISCUSSION
In a large, multicentre study of patients admitted with
AECOPD, we have confirmed that the DECAF score is a robust
predictor of mortality that can be easily scored at the bedside
using indices routinely available on admission. As in our earlier
study, DECAF was superior to other scores (BAP-65, CAPS,
APACHE II, CURB-65) sometimes used to predict short-term
mortality of patients with AECOPD.
We went to considerable lengths to capture consecutive
patients, but a small number of patients who died or who were
discharged shortly after admission may have been missed. In
order to minimise any resulting bias and to maximise capture of
all eligible patients, admission units were screened and a broad
coding records search was performed. In the 2014 UK national
audit,7 mean site recruitment of patients with spirometric con-
firmation of COPD was 0.36 per day. In our study, recruitment
was substantially higher at all sites (table 2), which supports
high case ascertainment rates. Investigators in site E reported
problems obtaining spirometry results, which may in part
explain their comparatively lower recruitment rate.
The CHARMS checklist provides guidance on the appraisal of
prediction model studies (see online supplementary material).18
The main limitation of this study is that the internal validation
study was, in part, performed retrospectively. Although retro-
spective collection of data may bias results, this risk was miti-
gated as the DECAF indices were collected as part of routine
clinical practice in the participating hospitals, the researchers
extracting data were blinded to outcome and case ascertainment
and outcome were similar to the prospective external cohort. Of
importance, the latter was individually adequately powered.
Data were only regarded as ‘missing’ once all data sources had
been checked and rates of missing data were low. For key out-
comes, analyses were repeated with and without multiple imput-
ation. To improve data completeness for DECAF, patients with
SaO2 >92% breathing room air, and judged by a clinician not to
require ABG analysis, scored 0 for the acidaemia component of
DECAF; this was justified by the low mortality in this group, and
supports a similar pragmatic approach in the clinical application
of the score, reducing burden for both patients and clinicians.
Table 4 DECAF score, inhospital mortality, sensitivity and specificity
Mortality by risk group*, % p Value
DECAF score n Died inhospital, n (%) Sensitivity Specificity Validation Derivation
0 255 0 (0) 1.00 0
1.0 1.4 0.60
1 519 8 (1.5) 1.00 0.16
2 498 27 (5.4) 0.94 0.48 5.4 8.4 0.14
3 301 46 (15.3) 0.73 0.78
21.4 34.7 0.00046
4 113 35 (31.0) 0.39 0.94
5 37 15 (40.5) 0.12 0.99
6 2 1 (50.0) 0.0076 1.00
Total 1725 132 (7.7) N/A N/A 7.7 10.4 0.016
*Risk groups: low=DECAF 0–1; intermediate=DECAF 2; high=DECAF 3–6.
Proportions of patients who died by risk group for validation and derivation cohort compared with Fisher’s exact test.
Table 5 Time to death in patients who died during the index admission and
median length of stay in those who survived to discharge, by DECAF score
DECAF
score
Median time to death, days
(IQR)
Median length of stay, days
(IQR)
0 N/A 3 (1–5)
1 4.5 (4–12.5) 4 (2–7)
2 9 (5–16) 5 (3–10)
3 10 (3.75–23.25) 7 (3–13)
4 5 (1–11) 7.5 (5–18)
5 2 (1–9) 10 (6–19.5)
6 2 (2–2) 22 (22–22)Figure 2 Receiver operator characteristic curves of prognostic scores
for 30-day mortality in patients with pneumonic exacerbations (n=489).
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However, we do not advise that this assumption is used to lower
clinician’s threshold for performing ABG sampling.
There were important differences between site populations, in
particular the receipt of institutional care, coexistent consolidation,
degree of airflow obstruction and severity of DECAF score. This
may in part reflect our efforts to select diverse sites for participation
in the study, and the strong and consistent performance of DECAF,
despite such differences in baseline characteristics, emphasises the
external validity of the score.
Mortality varied between sites (from 4.7% to 9.8%) and
between cohorts (internal validation=8.9% vs external valid-
ation=6.4%; p=0.057). This largely reflects differences in base-
line characteristics, notably the proportion of patients admitted
from institutional care and with coexistent pneumonia. When
these two subgroups were excluded, mortality was 4.8% in both
cohorts. Overall mortality was 7.7%, which is in keeping with
the 2003 (7.7%) and 2008 (7.8%) UK national audits. In the
2014 UK audit, mortality was 4.3% though the reason for the
lower mortality rate is reported as unknown. In our study, case
ascertainment, comorbidity and the proportion of patients with
consolidation or an MRCD score of 5 was higher than in the
2014 UK national audit.
Since our 2012 DECAF derivation study, two further prog-
nostic scores have been published.25 26 In one,25 patients with
acute ECG features of ischaemia and radiographic pulmonary
congestion were included. Such patients are unlikely to have
met our inclusion criterion of a primary diagnosis of AECOPD.
In the second study, the derived score showed good discrimin-
ation, and validation is awaited.26 However, the score included
subjective recognition of ‘use of inspiratory accessory muscles or
paradoxical breathing’, reducing generalisability, especially in
healthcare settings which lack specialist review within 24 h of
admission.7 27 Recruitment was lower than equivalent audit
data,27 because written patient consent was required, which dis-
proportionately excludes the lowest and highest risk patients.
Our methodology mirrored UK national audits; only routine
data were collected, so patient consent was not required.
LOS for AECOPD is falling, and early discharge, both supported
and unsupported, is commonplace, with patient selection based
largely on clinical judgement. However, clinical judgement of prog-
nosis is poor11 while the DECAF score has consistently shown a
high sensitivity for identifying low-risk patients. ESD and HAH
services for patients with AECOPD are expanding.7 National
Institute for Health and Care Excellence (NICE) recommend that
patient selection for these services be based on mortality risk,28
and also highlight the (previous) lack of a robust prognostic
score to guide decision-making. In the present study, DECAF
0–1 patients (including those with pneumonia or acidaemia)
had an acceptably low mortality risk and comprised 45% of
patients. The effect of treating this group with HAH or ESD
requires a randomised controlled trial (RCT) to assess clinical
outcomes and associated costs. We are currently undertaking an
RCT to address this question (ISRCTN 29082260). In our
experience, the CURB-65 score is commonly applied in patients
with pneumonic exacerbations of COPD to inform discharge
planning and choice of antibiotics. Evidence from both the der-
ivation and validation studies shows that clinicians should not
be reassured by ‘low risk’ CURB-65 scores in patients with
pneumonic AECOPD as the associated mortality is unaccept-
ably high. We advise against its use in this population.
A high-risk DECAF score is associated with both a high risk of
death and, in those who die, a short time to death. The latter is
particularly true of patients scoring DECAF 5 or 6, in whom the
median time to death was only 2 days. Such patients may be suit-
able for early escalation in care, or alternative palliative care, but
the window for intervention is short. Among patients who survive
to discharge, LOS increases incrementally with DECAF score.
In both the derivation and present study, dyspnoea severity
measured by the eMRCD score was the strongest single pre-
dictor of mortality and a superior predictor to the traditional
MRCD scale. In the 2014 UK national audit, ‘DECAF light’ was
scored retrospectively using the traditional MRCD scale (see
figure 3). However, ‘DECAF light’, as opposed to the full
DECAF score, was calculated only because eMRCD data was
unavailable. We support the recommendation of the UK national
audit that DECAF indices, including the eMRCD score, be col-
lected on all patients admitted with AECOPD. To allow hospi-
tals to meet this recommendation, we have included a figure of
the DECAF score which can be downloaded and incorporated
into COPD bundles and admission documentation (online sup-
plementary figure 1). Various versions of the traditional MRCD
scale exist,24 29 30 which may lead to differences in scoring. We
caution against such modifications to the eMRCD score unless
supported by empirical evidence.
Figure 3 Inhospital mortality (percentage and absolute number) in the DECAF derivation and validation study, and ‘DECAF light’ (see discussion)
from the 2014 UK National COPD Audit.
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In conclusion, we have shown that DECAF can be used in a
variety of hospital settings in order accurately to stratify mortal-
ity risk in patients with AECOPD. Further research is required
to quantify its impact on clinical practice, for example, in the
identification of patients for HAH or ESD services.
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